Basaglar and Lantus - What is the difference between them?
Medically reviewed by Drugs.com. Last updated on Nov 5, 2020.
Basaglar is an insulin glargine injection, approved in Dec 2015 and manufactured by Eli Lilly. Basaglar is a "follow-on" product to Lantus (insulin glargine injection), made by Sanofi-Aventis. However, the FDA does not consider Basaglar a biosimilar to Lantus. The FDA did not approve Basaglar as a biosimilar to Lantus because Lantus was not approved under the Public Health Service Act, so there is no “reference product” for a proposed biosimilar product.
They are both long-acting human insulin analogues used for blood glucose (sugar) control in adult and pediatric patients with type 1 diabetes, and in adults with type 2 diabetes.
Basaglar is administered subcutaneously once daily by the KwikPen at the same time every day.
See more with our drug comparison tool: www.drugs.com/compare/basaglar-vs-lantus
Related Medical Questions
- Levemir vs Lantus: What's the Difference?
- Does Lantus insulin need to be refrigerated?
- How long does Lantus last?
- How do you use the Lantus pen (Lantus SoloStar)?
- When should I take Lantus?
- Toujeo vs Lantus - What's the difference between them?
- Does Lantus insulin raise or lower your blood sugar?
- Which type of insulin has the longest duration of action?
- Is Tresiba the same as Lantus?
- Toujeo vs Tresiba - What's the difference between them?
- When is the best time to take Toujeo?
- How much Toujeo is too much?
- Does Lantus cause weight gain?
- How long can Toujeo stay out of the refrigerator?
- Can Toujeo be given twice a day?